title: Reduction in left ventricular wall stress and improvement in function in failing hearts using Algisyl-LVR.
abstract: Injection of Algisyl-LVR, a treatment under clinical development, is intended to treat patients with dilated cardiomyopathy. This treatment was recently used for the first time in patients who had symptomatic heart failure. In all patients, cardiac function of the left ventricle (LV) improved significantly, as manifested by consistent reduction of the LV volume and wall stress. Here we describe this novel treatment procedure and the methods used to quantify its effects on LV wall stress and function. Algisyl-LVR is a biopolymer gel consisting of Na(+)-Alginate and Ca(2+)-Alginate. The treatment procedure was carried out by mixing these two components and then combining them into one syringe for intramyocardial injections. This mixture was injected at 10 to 19 locations mid-way between the base and apex of the LV free wall in patients. Magnetic resonance imaging (MRI), together with mathematical modeling, was used to quantify the effects of this treatment in patients before treatment and at various time points during recovery. The epicardial and endocardial surfaces were first digitized from the MR images to reconstruct the LV geometry at end-systole and at end-diastole. Left ventricular cavity volumes were then measured from these reconstructed surfaces. Mathematical models of the LV were created from these MRI-reconstructed surfaces to calculate regional myofiber stress. Each LV model was constructed so that 1) it deforms according to a previously validated stress-strain relationship of the myocardium, and 2) the predicted LV cavity volume from these models matches the corresponding MRI-measured volume at end-diastole and end-systole. Diastolic filling was simulated by loading the LV endocardial surface with a prescribed end-diastolic pressure. Systolic contraction was simulated by concurrently loading the endocardial surface with a prescribed end-systolic pressure and adding active contraction in the myofiber direction. Regional myofiber stress at end-diastole and end-systole was computed from the deformed LV based on the stress-strain relationship.
authors.affiliation: Department of Surgery, UCSF/VA Medical Center, USA.
authors.forename: Lik Chuan
authors.initials: LC
authors.lastname: Lee
authors.forename: Zhang
authors.initials: Z
authors.lastname: Zhihong
authors.forename: Andrew
authors.initials: A
authors.lastname: Hinson
authors.forename: Julius M
authors.initials: JM
authors.lastname: Guccione
mesh_terms: D000464:Alginates / Q000008:administration & dosage* / Q000737:chemistry; D001672:Biocompatible Materials / Q000008:administration & dosage*; D005782:Gels / Q000008:administration & dosage*; D020723:Glucuronic Acid / Q000008:administration & dosage / Q000737:chemistry; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006603:Hexuronic Acids / Q000008:administration & dosage / Q000737:chemistry; D006801:Humans; D008279:Magnetic Resonance Imaging; D008955:Models, Cardiovascular; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D000464:Alginates; D001672:Biocompatible Materials; D005782:Gels; D006603:Hexuronic Acids; D020723:Glucuronic Acid